He Hailei, Wang Zhen, Fang Cuilin, Yan Junfeng
Department of Oral and Maxillofacial Surgery, Ganzhou People's Hospital, Ganzhou, Jiangxi, 341000, People's Republic of China.
Department of Stomatology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou, Zhejiang, 324000, People's Republic of China.
Int J Gen Med. 2024 Sep 16;17:4119-4126. doi: 10.2147/IJGM.S474142. eCollection 2024.
LIPH4 has been identified as an oncogenic lncRNA in different malignant diseases. This research aims to elucidate the link between the expression of LIPH4 and its prognostic application in tongue squamous cell carcinoma (TSCC).
To assess the expression of LIPH4, 142 TSCC and normal cases, respectively, which met the selection parameters, were used for qRT-PCR analysis. Furthermore, the association of LIPH4 expression with TSCC's clinicopathological features was identified via the Chi-square test. Moreover, the Kaplan-Meier test was used for calculating the survival rates, whereas the association of patient survival with prognostic factors was assessed with the help of Cox proportional hazard analysis.
The data indicated upregulated LIPH4 levels in TSCC samples than healthy samples. Furthermore, LIPH4 expression was associated with TSCC differentiation and stage, where increased expression indicated reduced disease-free survival (DFS) and overall survival (OS) rates. Additionally, advanced TSCC individuals with enhanced LIPH4 expression had reduced OS and DFS rates than those with reduced LIPH4 expression. Serum LIPH4 could be a promising diagnostic bio-index for TSCC, with an area under the curve of 0.8920 (95% CI = 0.8540-0.9299). These data revealed that the overexpression of LIPH4 might be a substantial prognostic factor for independently predicting the OS and DFS rates of TSCC patients.
Altogether, this research revealed that the expression of LIPH4 expression is closely associated with TSCC progression and, therefore, can be employed as a biomarker for its prognosis.
LIPH4已被确定为不同恶性疾病中的一种致癌长链非编码RNA。本研究旨在阐明LIPH4的表达与其在舌鳞状细胞癌（TSCC）中的预后应用之间的联系。
为评估LIPH4的表达，分别选取142例符合选择参数的TSCC病例和正常病例进行qRT-PCR分析。此外，通过卡方检验确定LIPH4表达与TSCC临床病理特征的相关性。而且，采用Kaplan-Meier检验计算生存率，同时借助Cox比例风险分析评估患者生存率与预后因素的相关性。
数据表明TSCC样本中LIPH4水平高于健康样本。此外，LIPH4表达与TSCC的分化和分期相关，其表达增加表明无病生存率（DFS）和总生存率（OS）降低。另外，LIPH4表达增强的晚期TSCC患者的OS和DFS率低于LIPH4表达降低的患者。血清LIPH4可能是TSCC一个有前景的诊断生物指标，曲线下面积为0.8920（95%CI = 0.8540 - 0.9299）。这些数据显示LIPH4的过表达可能是独立预测TSCC患者OS和DFS率的一个重要预后因素。
总之，本研究表明LIPH4的表达与TSCC进展密切相关，因此可作为其预后的生物标志物。
